Why is Concord Drugs falling/rising?

As of 07-Jul, Concord Drugs Ltd is experiencing a price increase, currently at Rs 52.87, reflecting a rise of 2.59 (5.15%). The stock has shown strong performance today, outperforming its sector by 5.23%. It reached an intraday high of Rs 52.87 and is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has surged by 27.83%, and it has delivered a remarkable 65.22% return over the past month, significantly outpacing the Sensex, which has only increased by 1.53% during the same period. Despite a decline in profits of -13% over the past year, the stock is trading at a discount compared to its peers, supported by a favorable valuation with a return on capital employed (ROCE) of 5.3.
In the broader market context, Concord Drugs has demonstrated a strong market-beating performance, with a year-to-date return of 39.13% compared to the Sensex's 6.79%. This indicates that investor sentiment is favorable towards the stock, likely due to its attractive valuation and recent positive trading activity, including a notable increase in delivery volume. However, it is important to note that the company has faced challenges, such as a -4.49% compound annual growth rate in operating profits over the last five years and a weak EBIT to interest ratio, which may raise concerns about its long-term fundamental strength. Nonetheless, the current momentum and positive short-term returns suggest that investors are optimistic about the stock's potential.